Whether you’re a young man who needs a little more testosterone, or a mature man who’s had to deal with an aging body, you may be wondering if your health insurance will cover testosterone replacement therapy. While some insurance plans do cover the use of testosterone for men with certain conditions, such as amyotrophic lateral sclerosis (ALS), there are other reasons why your plan might not cover testosterone treatment.
Insufficient evidence of effectiveness of testosterone for ALS
Despite its popularity, the evidence to support testosterone replacement therapy for ALS is somewhat limited. While the testosterone pill may have increased bone density, it was not shown to improve memory or cognition. Moreover, the number of major CV events was too small to draw strong conclusions.
The most important aspect of testosterone replacement therapy is its effect on muscle mass. ALS patients reported lower bioavailable testosterone levels, which may account for some of the muscle atrophy. In addition, androgens are thought to have trophic effects on lower motor neurons. Androgens also appear to have a modest effect on cognitive performance. A recent study found that testosterone therapy significantly increased total plaque volume and non-calcified plaque in the coronary arteries.
Another study found that testosterone therapy improved exercise capacity in patients with stable chronic heart failure. It also appears to improve quality of life. It is unclear whether or not testosterone treatment has a positive impact on other clinical outcomes such as symptom severity and patient satisfaction.
Insufficient evidence of effectiveness of testosterone for amyotrophic lateral sclerosis
ALS is a neurodegenerative disease caused by a lack of oxygen to the brain. Testosterone replacement therapy has been found to slow the progression of the disease. This could be due to the fact that testosterone has the capacity to reduce the amount of beta-amyloid in the brain.
Testosterone has been linked to a number of neurological conditions, such as Alzheimer’s disease and Parkinson’s disease. In discover the best Testosterone Therapy , low testosterone has been shown to increase the risk of vascular dementia. However, a link between low testosterone and ALS has not been conclusively proven. Testosterone replacement therapy has been found to increase muscle mass in ALS patients. Testosterone implants have also been shown to increase nerve regeneration and accelerate motor function.
It is also said that testosterone can be transferred across the blood-brain barrier by way of a transport protein. Testosterone levels in the brain decrease with age. The luteinizing hormone (lutein) helps to keep DHT levels in the CNS high. This may explain why ALS patients display a heightened testosterone level outside the CNS.
Insufficient evidence of effectiveness of testosterone for aging-related hypogonadism
Currently, testosterone replacement therapy (TRT) for aging-related hypogonadism has insufficient evidence of effectiveness. Although testosterone replacement therapy is recommended for improving cognition, mood and bone mineral density in young men with hypogonadism, the benefits and risks for older men are unknown.
Age-related hypogonadism (AOH) refers to an age-associated condition in which male testosterone concentrations decrease by approximately 1% to 2% per year. AOH is a biochemical syndrome, which can be caused by a variety of underlying conditions. https://www.google.com/maps?cid=3424385977669420479 is characterized by decreased erections, a decreased libido, reduced sexual desire, and genital abnormalities.
AOH is not a primary condition, although it is often associated with obesity and metabolic disease. AOH symptoms tend to be slow in onset and may occur over years. Symptoms are most prominent in the areas of sexual dysfunction and erection loss. A physical exam should be performed to confirm a diagnosis of hypogonadism.
TRT for aging-related hypogonadism is not approved by the FDA. Although the FDA is charged with regulating the pharmaceutical industry, it does not dictate how doctors treat patients. Currently, doctors use clinical guidelines to determine the best treatments.
Insufficient evidence of effectiveness of testosterone for chronic HF
Despite evidence of beneficial effects on cardiorespiratory and metabolic parameters in heart failure (HF) patients, testosterone replacement therapy has not been adequately analyzed in HF patients. To further explore extraordinary IV infusions of testosterone in HF patients, adequately powered randomized controlled trials (RCTs) are needed to assess its benefits and safety.
The testosterone study was a double-blind, randomized, placebo-controlled trial, which was conducted at four specialized HF clinics in Spain. The testosterone group received intramuscular injections of testosterone every two weeks for 12 weeks. The testosterone group did not differ from the placebo group in body mass index (BMI), body fat percentage, weight, blood pressure, heart rate, or systolic blood pressure. Moreover, testosterone did not affect the plasma concentrations of cytokines, high density lipoprotein cholesterol, or total and free testosterone.
Testosterone therapy also increased bone mineral density (BMD) in older hypogonadal men, resulting in higher levels of BMD in the spine and hips. Moreover, testosterone treatment was associated with a decrease in the rate of clinical events, a reduction in disability, and an improvement in myocardial structure.
18133 Ventura Blvd Suite C, Tarzana, CA 91356